# A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

> **NCT03608501** · PHASE2 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Thalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03608501
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-30
- **Primary completion:** 2021-06-30
- **Final completion:** 2023-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision (no safety or efficacy concerns)
- **Last updated:** 2020-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03608501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03608501, "A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03608501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*